Ammonium Chloride

Summary

Ammonium Chloride (CHEMBL1200939) is an approved small-molecule ferroptosis inhibitor (ATC B05XA04) targeting TRPA1.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B05XA04 (+1 more)
• Targets: 1 (TRPA1)
• Clinical trials: 3
• Chemistry: 53.49 Da · ClH4N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200939
Name	Ammonium Chloride
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	12820921
ChEBI	CHEBI:31206
ATC	B05XA04, G04BA01
Molecular formula	ClH4N
Molecular weight	53.49
InChIKey	NLXLAEXVIDQMFP-UHFFFAOYSA-N

SMILES: N.Cl

IUPAC name: azane;hydrochloride

ChEBI definition: An inorganic chloride having ammonium as the counterion.

Pharmacological roles (ChEBI): ferroptosis inhibitor.

Also known as: Ammonium chloride, Ammonium chloride ((nh4)cl), Ammonium muriate, Ammonium muriaticum, Amoklor, Catalyst rd, Chlorammonic, Darammon, E 510, E-510, E510, FEMA NO. 4494

Patent coverage: 210,337 distinct patent families (539,472 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 539,218 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TRPA1	TRPA1	Activation	2	0.1%	O75762

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): TRPA1.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
TRP channels	1	TRPA1

Dominant GO biological processes

GO term	Targets
monoatomic ion transport	1
intracellular calcium ion homeostasis	1
cell surface receptor signaling pathway	1
response to cold	1
response to xenobiotic stimulus	1
urinary bladder smooth muscle contraction	1
sensory perception of pain	1
cellular response to heat	1
positive regulation of insulin secretion involved in cellular response to glucose stimulus	1
response to pain	1
thermoception	1
detection of mechanical stimulus involved in sensory perception of pain	1
detection of chemical stimulus involved in sensory perception of pain	1
protein homotetramerization	1
cellular response to hydrogen peroxide	1

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06209359	PHASE1	RECRUITING	Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
NCT01440478	PHASE1	COMPLETED	The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects
NCT06942312	Not specified	ENROLLING_BY_INVITATION	Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

27 molecules share ≥1 primary target. Top 27 by shared-target count:

Molecule	Source	Status	Shared targets
DICLOFENAC	ChEMBL + PubChem	Phase 4 (approved)	TRPA1
DISULFIRAM	ChEMBL + PubChem	Phase 4 (approved)	TRPA1
MEFENAMIC ACID	ChEMBL + PubChem	Phase 4 (approved)	TRPA1
MENTHOL	ChEMBL	Phase 4 (approved)	TRPA1
NICOTINE	ChEMBL	Phase 4 (approved)	TRPA1
RESVERATROL	ChEMBL + PubChem	Phase 3 (approved)	TRPA1
CANNABINOL	ChEMBL	Phase 3	TRPA1
ICILLIN	ChEMBL	Phase 3	TRPA1
LEVOMENTHOL	ChEMBL	Phase 3	TRPA1
ALLICIN	ChEMBL	Phase 2	TRPA1
CANNABIDIVARIN	ChEMBL	Phase 2	TRPA1
CANNABIGEROL	ChEMBL	Phase 2	TRPA1
CARVACROL	ChEMBL	Phase 2	TRPA1
CHLORDANTOIN	ChEMBL	Phase 2	TRPA1
FLUFENAMIC ACID	ChEMBL	Phase 2	TRPA1
RG6341	ChEMBL	Phase 2	TRPA1
SALIRASIB	ChEMBL	Phase 2	TRPA1
SANGUINARIUM	ChEMBL	Phase 2	TRPA1
TETRAHYDROCANNABIVARIN	ChEMBL	Phase 2	TRPA1
THYMOL	ChEMBL	Phase 2	TRPA1
Acetaldehyde	PubChem	Approved	TRPA1
Caffeine	PubChem	Approved	TRPA1
camphor (synthetic)	PubChem	Approved	TRPA1
dronabinol	PubChem	Approved	TRPA1
Eugenol	PubChem	Approved	TRPA1
menthol, unspecified form	PubChem	Approved	TRPA1
Propylene Glycol	PubChem	Approved	TRPA1